National Association of Testing Authorities, Australia
Scope of Accreditation
Australian Clinical Labs
Site
Osborne Park Laboratory
Accreditation No.
20102
Site No.
2906
Date of Accreditation
04 Jun 1990
Contact
Ms Alicia Cann P: +61 (08) 94427604
Availability
Services available to external clients
Supervision
GY (General)
Scope of Accreditation
Biochemistry
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of calculus | Calculi | Ammonium; Calcium; Carbonate; Cysteine; Magnesium; Oxalate; Phosphate; Uric acid |
| Chemical pathology - Detection and/or quantitation of tumour markers | Plasma; Serum | β2-Microglobulin (B2M) |
| CA125 antigen (CA125); CA15-3 antigen (CA15-3) | ||
| CA19-9 antigen (CA19-9); Carcinoembryonic antigen (CEA) | ||
| Serum | Prostate specific antigen (PSA) | |
| Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Plasma | Parathyroid hormone (PTH) |
| Plasma; Serum | Cortisol | |
| Serum | Testosterone | |
| Prolactin | ||
| Testosterone | ||
| Follicle stimulating hormone (FSH); Insulin; Luteinising hormone (LH); Oestradiol; Procalcitonin; Progesterone; α-Fetoprotein (AFP) | ||
| Macroprolactin | ||
| C-peptide; Dehydroepiandrosterone sulfate (DHEAS); Sex hormone binding globulin (SHBG) | ||
| Anti-Mullerian hormone (AMH) | ||
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
| Chemical pathology - Further investigation of cardiac function | Plasma; Serum | Troponin |
| Chemical pathology - Further investigation of renal and/or hepatic function | Plasma; Serum | Caeruloplasmin |
| Plasma; Serum; Urine | Uric acid | |
| Serum | Haptoglobins | |
| α1-Antitrypsin | ||
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Ascitic fluid; Drainage fluid; Pleural fluid | Albumin; Amylase; Bilirubin - Total; Chloride; Cholesterol - Total; Creatinine; Glucose; Lactate dehydrogenase (LDH); Potassium; Protein - Total; Sodium; Triglycerides; Urea |
| Plasma; Serum | Alanine aminotransferase; Albumin; Alkaline phosphatase; Amylase; Aspartate aminotransferase; Bicarbonate; Bilirubin - Direct; Bilirubin - Total; C-reactive protein (CRP); Calcium - Total; Chloride; Cholesterol - Total; Creatine kinase; Creatinine; Glucose; HDL - Quantitation; High sensitivity C-reactive protein (CRP); Lactate dehydrogenase (LDH); Lipase; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urea; γ-Glutamyltransferase | |
| Urine | Calcium - Total; Chloride; Creatinine; Microalbumin; Phosphate; Potassium; Protein - Total; Sodium; Urea | |
| Chemical pathology - Investigation for folate deficiency | Serum | Folate |
| Chemical pathology - Investigation of Helicobacter pylori colonisation or eradication | Breath | C14 |
| Chemical pathology - Investigation of maternal markers to detect foetal abnormality | Serum | Free β-human chorionic gonadotropin (free β-hCG); Pregnancy associated plasma protein A (PAPP-A) |
| Chemical pathology - Iron studies | Plasma; Serum | Ferritin; Iron; Transferrin |
| Chemical pathology - Quantitation of vitamin B markers | Serum | Holotranscobalamin (active vitamin B12) |
| Chemical pathology - Quantitation of vitamins | Serum | Cobalamin (vitamin B12); Vitamin D |
| Chemical pathology - Tests for thyroid function | Serum | Thyroid stimulating hormone (TSH); Thyroxine (T4) - Free; Triiodothyronine (T3) - Free |
| Infertility and pregnancy tests including assisted reproductive technology - Diagnosis or follow up of threatened abortion and/or diagnosis of ectopic pregnancy | Serum | Human chorionic gonadotropin (hCG) - Quantitative total |
Ellenbrook Collection Centre (Fixed)
ISO 15189 (2022)
Legal
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure - Testing performed at permanent fixed sites | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates; Oxidants; Specific gravity; pH |
Haematology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Assessment of haemolysis or metabolic enzymes (red cell enzyme assays) | Blood | Glucose-6-phosphate dehydrogenase (G6PD) |
| Haematology - Bone marrow examination | Bone marrow | Examination of aspirated material |
| Haematology - Diagnosis of thalassemia | Blood | Haemoglobin A2 (HbA2) - Quantitation; Haemoglobin F (HbF) - Quantitation |
| Haematology - Examination of blood films by special staining | Blood | Malaria |
| Bone marrow | Iron | |
| Haematology - Full blood examination | Blood | Morphology |
| Differential number; Erythrocyte count (red blood cell count, RBCC); Haemoglobin (Hb); Leucocyte count (white blood cell count, WBCC); Platelet count; Red blood cell index or indices; Reticulocytes | ||
| Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Blood | Platelet function (PFA) |
| Plasma | Anti-thrombin III; Factor IX; Factor VIII; Lupus anticoagulant; Protein C and protein S | |
| Von Willebrand factor (vWF) activity - Ristocetin co-factor assay; Von Willebrand factor (vWF) antigen - Quantitation | ||
| Activated partial thromboplastin time (APTT); D-dimer; Fibrinogen; International normalised ratio (INR); Prothrombin time (PT); Thrombin time (TT) | ||
| Haematology - Investigation of haemoglobinopathy (excluding thalassemia) | Blood | Haemoglobin fraction (S, C, D, E) - Quantitation |
| Haematology - Limited blood examination | Blood | Erythrocyte (RBC) sedimentation rate (ESR) |
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Blood | Malaria |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood; Plasma; Serum | Infectious mononucleosis |
Immunology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Plasma; Serum | Anti-nuclear antibodies (ANA) |
| Anti-thyroid stimulation immunoglobulin antibodies (TSI) | ||
| Serum | Rheumatoid factor | |
| Anti-Streptococcal DNase B | ||
| Anti-gastric parietal cell antibodies (GPC/PCA); Anti-glomerular basement membrane antibodies (anti-GBM); Anti-liver-kidney microsomes antibodies (LKM); Anti-mitochondrial antibodies (AMA, AMA M1 and/or AMA M2); Anti-neutrophil cytoplasmic antibodies (ANCA); Anti-smooth muscle antibodies (SMA) | ||
| Anti-thyroid stimulating hormone receptor antibodies (TSHRAb) | ||
| Anti-cyclic citrullinated peptide antibodies (CCP) | ||
| Anti-thyroglobulin antibodies (Tg); Anti-thyroid peroxidase antibodies (TPO) | ||
| Anti-gastric parietal cell antibodies (GPC/PCA); Anti-glomerular basement membrane antibodies (anti-GBM); Anti-liver-kidney microsomes antibodies (LKM); Anti-mitochondrial antibodies (AMA, AMA M1 and/or AMA M2); Anti-neutrophil cytoplasmic antibodies (ANCA); Anti-smooth muscle antibodies (SMA) | ||
| Anti-double stranded DNA antibodies (dsDNA); Anti-extractable nuclear antigen antibodies (ENA); Anti-gliadin antibodies (AGA); Anti-intrinsic factor antibodies (IF); Anti-myeloperoxidase antibodies (MPO); Anti-proteinase 3 antibodies (PR3); Anti-tissue transglutaminase antibodies (tTG) | ||
| Anti-cyclic citrullinated peptide antibodies (CCP) | ||
| Anti-double stranded DNA antibodies (dsDNA); Anti-extractable nuclear antigen antibodies (ENA); Anti-gliadin antibodies (AGA); Anti-intrinsic factor antibodies (IF); Anti-myeloperoxidase antibodies (MPO); Anti-proteinase 3 antibodies (PR3); Anti-tissue transglutaminase antibodies (tTG) | ||
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential drug allergens) | Serum | Amoxicilloyl group; Ampicilloyl group; Penicilloyl G; Penicilloyl V |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential epidermal and animal protein allergens) | Serum | Cat dander; Cat epithelium; Cow dander; Dog dander; Horse dander |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [egg and fowl] allergens) | Serum | Egg white |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fish, shellfish and molluscs] allergens) | Serum | Blue mussel; Codfish; Crab; Lobster; Prawn; Salmon; Shrimp; Squid; Tuna |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fruit and vegetable] allergens) | Serum | Fruit mix; Orange citrus |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [milk] allergens) | Serum | Milk |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [seeds, legumes and nuts] allergens) | Serum | Almond; Brazil nut; Cashew nut; Cereal mix; Coconut; Gluten; Hazelnut; Peanut; Soy bean; Walnut; Wheat |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential grass pollen allergens) | Serum | Kentucky plane (June) grass; Meadow grass; Orchard grass; Timothy grass |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential insect allergens) | Serum | Cockroach; German cockroach |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential microorganism allergens) | Serum | Alternaria tenius; Aspergillus fumigatus; Candida albicans; Cladosporium herbarum; Penicillium chrysogenum (formerly Penicillium notatum) |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential mite allergens) | Serum | Dermatophagoides farinae house dust mite; Dermatophagoides pteronyssinus house dust mite; House dust - Greer |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential occupational allergens) | Serum | Latex |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential tree pollen allergens) | Serum | Acacia; Eucalyptus; Melaleuca; Olive; White pine; Willow salix |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential venom allergens) | Serum | Bee venom; European paper wasp venom |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential weed pollen allergens) | Serum | Weed mix |
| Immunopathology - Quantitation of complement proteins | Serum | Complement components C3 and C4 |
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Plasma; Serum | Cryoglobulins |
| Serum | Detection and quantitation of free kappa and free lambda light chains | |
| Serum; Urine | Protein classes | |
| Urine | Detection of Bence Jones proteins | |
| Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Serum | Immunoglobulin subclasses; Total immunoglobulin M |
| Total immunoglobulin A; Total immunoglobulin G | ||
| Total immunoglobulin E |
Microbiology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Detection of faecal occult blood | Faeces | Haemoglobin (Hb) |
| Infertility and pregnancy tests including assisted reproductive technology - Semen analysis (other than post vasectomy) | Semen | Motility; Sperm number |
| Infertility and pregnancy tests including assisted reproductive technology - Semen analysis for post vasectomy and/or examination of cervical mucus | Semen | Presence of spermatozoa |
| Microbiology - Bacteriology - Detection of pathogenic bacteria | Aspirates; Blood; Cerebrospinal fluid (CSF); Ear swabs; Faeces; Fluids; Genital swabs; Nasal swabs; Red cell concentrates; Respiratory specimens; Sputum; Synovial fluid; Throat swabs; Tissues; Urine; Wound swabs | Bacteria; Pathogenic identification and antibiotic susceptibility |
| Aspirates; Blood; Cerebrospinal fluid (CSF); Ear swabs; Faeces; Fluids; Genital swabs; Nasal swabs; Respiratory specimens; Sputum; Synovial fluid; Throat swabs; Tissues; Urine; Wound swabs | Bacteria; Pathogenic identification and antibiotic susceptibility | |
| Bacteria; Pathogenic microorganisms | ||
| Bacteria; Pathogenic identification and antibiotic susceptibility | ||
| Aspirates; Blood; Cerebrospinal fluid (CSF); Ear swabs; Fluids; Genital swabs; Nasal swabs; Respiratory specimens; Sputum; Synovial fluid; Throat swabs; Tissues; Urine; Wound swabs | Bacteria; Casts; Crystals; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | |
| Blood | Bacteria; Pathogenic microorganisms | |
| Urine | Bacteria; Casts; Epithelial cells; Erythrocytes (red blood cells, RBC); Glucose; Leucocytes (white blood cells, WBC); Proteins; pH | |
| Blood; Glucose; Proteins; pH | ||
| Microbiology - Bacteriology - Detection of pathogenic bacteria for epidemiological infection control surveillance | Axilla swabs; Groin swabs; Nasal swabs; Perianal swabs; Throat swabs; Wounds | Methicillin resistant Staphylococcus aureus (MRSA) |
| Faeces; Rectal swabs | Vancomycin resistant Enterococci (VRE) | |
| Rectal swabs | Carbapenem resistant Enterobacteriaceae (CRE) | |
| Microbiology - Environmental investigations and/or infection control (Clinical non-human testing) | Gastrointestinal endoscopes; Vascular catheter tips | Bacterial growth - Sterility |
| Spore strips | Bacterial growth - Sterility | |
| Microbiology - Mycobacteriology - Detection and identification of mycobacteria | Respiratory specimens; Sputum | Mycobacteria identification |
| Microbiology - Mycobacteriology - Tests for cell mediated immunity | Blood | Latent tuberculosis |
| Microbiology - Mycology - Detection of dermatophytes and other fungi causing cutaneous disease | Skin | Dermatophyte identification |
| SkinGel swab to be added | Dermatophyte identification | |
| Microbiology - Mycology - Detection, isolation and/or identification of yeasts and/or fungal elements | Cerebrospinal fluid (CSF); Fluids; Respiratory specimens; Sputum; Tissues | Fungi identification; Yeasts identification |
| Fungi identification; Yeasts identification | ||
| Fungi identification; Yeasts identification | ||
| Isolates | Yeast susceptibility | |
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Faeces | Cysts; Ova; Parasites |
Midland Collection Centre (Fixed)
ISO 15189 (2022)
Legal
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure - Testing performed at permanent fixed sites | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates; Oxidants; Specific gravity; pH |
Molecular Infectious
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (bacteria) | Dry swabs; Liquid based cytology specimens; Urine | Neisseria gonorrhoeae |
| Chlamydia trachomatis; Neisseria gonorrhoeae | ||
| Faeces | Campylobacter spp.; Clostridioides difficile; Salmonella spp.; Shigella spp.; Shiga toxin | |
| Nasopharyngeal swabs | Bordetella pertussis | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Faeces | Blastocystis hominis; Cryptosporidium spp.; Dientamoeba fragilis; Entamoeba histolytica; Giardia intestinalis |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Dry swabs | Herpes simplex virus (HSV); Varicella zoster virus (VZV) |
| Dry swabs; Nasal swabs; Nasopharyngeal and throat swab; Nasopharyngeal aspirate | Adenovirus; Human metapneumovirus; Influenza A virus; Influenza B virus; Parainfluenza virus type 1/2/3/4; Respiratory syncytial virus (RSV); Rhinovirus | |
| Faeces | Adenovirus F40; Adenovirus F41; Astrovirus; Norovirus G1; Norovirus G2; Rotavirus A; Sapovirus I; Sapovirus II; Sapovirus IV; Sapovirus V | |
| Nasal swabs; Nasopharyngeal swabs; Oropharyngeal swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) - TMA | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Nasal swabs; Nasopharyngeal swabs; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Nasopharyngeal swabs | Adenovirus; Human metapneumovirus; Influenza A virus; Influenza B virus; Parainfluenza virus type 1/2/3/4; Respiratory syncytial virus (RSV); Rhinovirus | |
| Microbiology - Molecular biology - Surveillance programme for the detection of microbial nucleic acids (viruses) in accordance with Commonwealth and/or State Health protocols | Saliva | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) |
Osborne Park Collection Centre (Fixed)
ISO 15189 (2022)
Legal
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure - Testing performed at permanent fixed sites | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates; Oxidants; Specific gravity; pH |
Quinns Rocks Collection Centre (Fixed)
ISO 15189 (2022)
Legal
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure - Testing performed at permanent fixed sites | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates; Oxidants; Specific gravity; pH |
Rockingham Collection Centre (Fixed)
ISO 15189 (2022)
Legal
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure - Testing performed at permanent fixed sites | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates; Oxidants; Specific gravity; pH |
Serology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood; Plasma; Serum | Hepatitis A virus (HAV); Hepatitis B virus (HBV); Hepatitis C virus (HCV); Human immunodeficiency virus (HIV); Rubella IgG antibody; Syphilis Treponema pallidum antibody; Toxoplasma |
| Plasma; Serum | Bordetella pertussis total antibody; Epstein-Barr virus IgG antibody; Epstein-Barr virus IgM antibody; Epstein-Barr virus nuclear antigen; Epstein-Barr virus; Hepatitis C virus (HCV); Herpes simplex virus type 2 antibody (anti-HSV2) - IgG; Herpes simplex type 1 antibody (anti-HSV1) - IgG; Human immunodeficiency virus (HIV); Measles IgG antibody; Mumps virus IgG antibody; Mycoplasma pneumoniae; Parvovirus; Varicella zoster virus (VZV) IgG antibody | |
| Anti-streptolysin O (ASOT) | ||
| Serum | Mycoplasma spp. | |
| Cytomegalovirus (CMV); Cytomegalovirus antibody (anti-CMV) IgG; Helicobacter pylori | ||
| Syphilis Treponema pallidum antibody | ||
| Syphilis Treponema pallidum antibody |
Thornlie Collection Centre (Fixed)
ISO 15189 (2022)
Legal
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure - Testing performed at permanent fixed sites | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates; Oxidants; Specific gravity; pH |
Toxicology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Urine | Alcohol; Barbiturates; Methadone |
ISO 15189 (2022)
Legal
Medicare expiry date
26 Aug 2025
Last Activity Date
27 Feb 2024
| Service | Product | Determinant |
|---|---|---|
| Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure - Testing performed at client sites | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates; Oxidants; Specific gravity; pH |
| Medico legal drug testing AS/NZS 4308:2008, section 2 Specimen collection, storage, handling and dispatch | Urine | Colour; Creatinine; Temperature; pH |
| Medico legal drug testing AS/NZS 4308:2008, section 3 General laboratory requirements | Urine | General laboratory requirements as described in AS/NZS 4308 |
| Medico legal drug testing AS/NZS 4308:2008, section 4 Laboratory screening procedures | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Opiates |
| Medico legal drug testing AS/NZS 4308:2008, section 5 Laboratory confirmatory procedures | Urine | 11-nor-δ-9-Tetrahydrocannabinol-9-carboxylic acid; 6-Acetylmorphine; 7-Amino-clonazepam; 7-Amino-flunitrazepam; 7-Amino-nitrazepam; Amphetamines; Benzoylecgonine (ecgonine benzoate); Codeine; Diazepam; Ecgonine methyl ester; Methylamphetamine; Methylenedioxyamphetamine; Morphine; Nordiazepam; Oxazepam; Phentermine; Pseudoephedrine (PSE); Temazepam; α-Hydroxyalprazolam |
| Medico legal drug testing AS/NZS 4760, appendix A On-site screening procedure - Testing performed at client sites | Oral fluid | Amphetamine type substances; Cannabinoids; Cocaine; Cocaine metabolites; Opiates; Oxycodone; Δ-9-Tetrahydrocannabinol (THC-Δ9) |
| Medico legal drug testing AS/NZS 4760, appendix A On-site screening test procedure | Oral fluid | Amphetamine type substances; Cannabinoids; Cocaine; Cocaine metabolites; Opiates; Oxycodone; Δ-9-Tetrahydrocannabinol (THC-Δ9) |
| Medico legal drug testing AS/NZS 4760, appendix B Additional testing | Oral fluid | Benzodiazepines; Diazepam; Nordiazepam; Oxazepam; Phentermine; Temazepam |
| Medico legal drug testing AS/NZS 4760, section 2 Collection, storage, handling and dispatch | Oral fluid | Handling and dispatch; Sample collection and storage |
| Medico legal drug testing AS/NZS 4760, section 3 General laboratory requirements | Oral fluid | General laboratory requirements as described in AS/NZS 4760 |
| Medico legal drug testing AS/NZS 4760, section 4 Laboratory screen testing | Oral fluid | 6-Acetylmorphine; Amphetamines; Benzoylecgonine (ecgonine benzoate); Cocaine; Codeine; Methylamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Morphine; Oxycodone; Δ-9-Tetrahydrocannabinol (THC-Δ9) |
| Medico legal drug testing AS/NZS 4760, section 5 Laboratory confirmatory procedures | Oral fluid | 3,4-Methylenedioxyamphetamine (MDA); 3,4-Methylenedioxymethamphetamine (MDMA); 6-Acetylmorphine; Amphetamines; Benzoylecgonine (ecgonine benzoate); Cocaine; Codeine; Methylamphetamine; Morphine; Oxycodone; Δ-9-Tetrahydrocannabinol (THC-Δ9) |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
20102
Site No.
2906
Print date
26 Nov 2024
END OF SCOPE